货号：N8451

储存条件：粉末-20°C可保存3年；液体-80°C可保存12月。

产品描述

STAT3, the protein most linked to tumorigenesis in STAT family and regarded as a target for cancer therapy, is constitutively activated in most human solid tumors and is involved in the proliferation, angiogenesis, immune evasion, and anti-apoptosis of cancer cells. Napabucasin is a STAT3 inhibitor. Napabucasin is usually used in cancer stemness research. Treatment with Napabucasin at concentration of 1μM or 2μM for 6h or 24h could inhibited self-renewal genes expression, including β-catenin, Nanog, Smo and Sox2 in FaDu cancer stem cells, while the chemotherapeutic agents gemcitabine or carboplatin either had no effect or resulted in increased cancer stem cell gene expression. Pretreatment with Napabucasin at concentration of 2μM for 48h blocked spherogenesis of spheres derived from DLD1 and HCT116 cell lines, while imatinib, sunitinib, erlotinib, or doxorubicin had little effect, suggesting the inhibition of self-renewal of stemness-high cancer cells by Napabucasin. Daily administration of 20mg/kg BBI608, i.p., for 14 days, decreased the stemness-high subpopulation by five and four folds in Paca-2 and FaDu models, respectively.

产品信息